In summary, our findings demonstrate that BTK gene expression in the MS brain is significantly increased in two types of lesions, the active and chronic active lesions, both characterized by presence of B cells and microglia that are cellular targets of BTKi. Here, BTK is linked to myeloid sarcoma.